お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:世界の治療的血漿交換(TPE)市場:産業分析、市場規模、シェア、成長、動向、予測 2018年~2026年
市場調査レポート
商品コード
674844

世界の治療的血漿交換(TPE)市場:産業分析、市場規模、シェア、成長、動向、予測 2018年~2026年

Therapeutic Plasma Exchange Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

出版日: | 発行: Transparency Market Research | ページ情報: 英文 161 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.93円
世界の治療的血漿交換(TPE)市場:産業分析、市場規模、シェア、成長、動向、予測 2018年~2026年
出版日: 2018年07月26日
発行: Transparency Market Research
ページ情報: 英文 161 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の治療的血漿交換(TPE)市場を調査し、市場の概要、適応症・エンドユーザー・地域別の市場動向、市場規模の推移と予測、成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査範囲と市場区分
  • 調査のハイライト

第2章 前提条件と調査方法

  • 前提条件
  • 調査方法

第3章 エグゼクティブサマリー

  • 市場概要
  • 市場シェア:地域別

第4章 市場概要

  • 市場区分
  • 市場規模の推移と予測
  • 市場の見通し
  • 主要産業イベント

第5章 市場のダイナミクス

  • 成長要因と阻害要因の分析
  • 成長要因
  • 阻害要因
  • 市場機会
  • 主要動向
  • パイプライン分析
  • 主要適応症への臨床効果
  • 償還シナリオ
  • 主要疾患の世界的な有病率
  • ヘルスケアの概要

第6章 世界の治療的血漿交換(TPE)処置件数:地域/国別

第7章 世界の治療的血漿交換(TPE)市場:適応症別

  • イントロダクション
  • 市場シェア分析:適応症別
  • 市場規模の推移と予測:適応症別
    • 神経疾患
    • 腎疾患
    • 血液疾患
    • 代謝異常
    • その他
  • 市場魅力分析:適応症別

第8章 世界の治療的血漿交換(TPE)市場:エンドユーザー別

  • イントロダクション
  • 市場シェア分析:エンドユーザー別
  • 市場規模の推移と予測:エンドユーザー別
    • 病院
    • 専門クリニック
    • 外来外科センター
  • 市場魅力分析:エンドユーザー別

第9章 世界の治療的血漿交換(TPE)市場:地域別

  • 市場シェア分析:地域別
  • 市場規模の推移と予測:地域別
  • 市場魅力分析:地域別

第10章 北米

第11章 欧州

第12章 アジア太平洋

第13章 ラテンアメリカ

第14章 中東・アフリカ

第15章 企業プロファイル

  • 競争マトリックス
  • 会社概要
    • 旭化成
    • Baxter International, Inc.
    • テルモ
    • B. Braun Melsungen AG
    • Fresenius Kabi AG
    • 川澄化学工業
    • Haemonetics Corporation
    • Cerus Corporation
    • Hemacare Corporation
    • Medica SpA
図表

List of Tables

  • Table 01: Global Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Region, 2017
  • Table 02: Global Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Disease Indication, 2017
  • Table 03: North America Therapeutic Plasma Exchange Market Size (US$ Mn), by Country and Number of TPE Procedures, 2017
  • Table 04: Europe Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Country/Sub-region, 2017
  • Table 05: Asia Pacific Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Country/Sub-region, 2017
  • Table 06: Latin America Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Country/Sub-region, 2017
  • Table 07: Middle East & Africa Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Country/Sub-region, 2017
  • Table 08: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 09: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016-2026
  • Table 10: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016-2026
  • Table 11: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016-2026
  • Table 12: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016-2026
  • Table 13: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • Table 14: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Region, 2016-2026
  • Table 15: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication,
  • Table 16: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016-2026
  • Table 17: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016-2026
  • Table 18: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016-2026
  • Table 19: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016-2026
  • Table 20: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • Table 21: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country, 2016-2026
  • Table 22: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2018-2026
  • Table 23: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders,
  • Table 24: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016-2026
  • Table 25: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders,
  • Table 26: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016-2026
  • Table 27: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • Table 28: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 29: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 30: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016-2026
  • Table 31: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016-2026
  • Table 32: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016-2026
  • Table 33: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016-2026
  • Table 34: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • Table 35: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country, 2016-2026
  • Table 36: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 37: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016-2026
  • Table 38: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016-2026
  • Table 39: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016-2026
  • Table 40: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016-2026
  • Table 41: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • Table 42: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 43: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2018-2026
  • Table 44: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016-2026
  • Table 45: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016-2026
  • Table 46: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016-2026
  • Table 47: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016-2026
  • Table 48: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • Table 49: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2016-2026

List of Figures

  • Figure 01: Global Therapeutic Plasma Exchange Market Snapshot
  • Figure 02: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2016-2026
  • Figure 03: Market Value Share by Disease Indication (2017)
  • Figure 04: Market Value Share by End-user (2017)
  • Figure 05: Market Value Share by Region (2017)
  • Figure 06: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2017 and 2026
  • Figure 07: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Neurological Disorders, 2017 and 2026
  • Figure 08: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Renal Disorders, 2017 and 2026
  • Figure 09: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Hematology Disorders, 2017 and 2026
  • Figure 10: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Metabolic Disorders, 2017 and 2026
  • Figure 11: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Neurological Disorders, by 2016-2026
  • Figure 12: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Renal Disorders, by 2016-2026
  • Figure 13: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Hematology Disorders, by 2016-2026
  • Figure 14: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Metabolic Disorders, by 2016-2026
  • Figure 15: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Other, by 2016-2026
  • Figure 16: Global Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication
  • Figure 17: Global Therapeutic Plasma Exchange Market Value Share, by End-user, 2017 and 2026
  • Figure 18: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals, 2016-2026
  • Figure 19: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Specialty Clinics, 2016-2026
  • Figure 20: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ambulatory Surgical Centers, 2016-2026
  • Figure 21: Global Therapeutic Plasma Exchange Market Attractiveness, by End-user
  • Figure 22: Global Therapeutic Plasma Exchange Market Value Share, by Region, 2017 and 2026
  • Figure 23: Global Therapeutic Plasma Exchange Market Attractiveness, by Region
  • Figure 24: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 25: North America Market Attractiveness Analysis, by Country
  • Figure 26: North America Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2017 and 2026
  • Figure 27: North America Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2017 and 2026
  • Figure 28: North America Therapeutic Plasma Exchange Market Value Share Analysis, by Country, 2017 and 2026
  • Figure 29: North America Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication
  • Figure 30: North America Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user
  • Figure 31: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 32: Europe Market Attractiveness Analysis, by Country/Sub-region
  • Figure 33: Europe Therapeutic Plasma Exchange Market Value Share Analysis by Disease Indication, 2017 and 2026
  • Figure 34: Europe Therapeutic Plasma Exchange Market Value Share Analysis by End-user, 2017 and 2026
  • Figure 35: Europe Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 36: Europe Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication
  • Figure 37: Europe Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user
  • Figure 38: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 39: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region
  • Figure 40: Asia Pacific Therapeutic Plasma Exchange Market Value Share Analysis by Disease Indication, 2017 and 2026
  • Figure 41: Asia Pacific Therapeutic Plasma Exchange Market Value Share Analysis by End-user, 2017 and 2026
  • Figure 42: Asia Pacific Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 43: Asia Pacific Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication
  • Figure 44: Asia Pacific Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user
  • Figure 45: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 46: Latin America Market Attractiveness Analysis, by Country/Sub-region
  • Figure 47: Latin America Therapeutic Plasma Exchange Market Value Share Analysis by Disease Indication, 2017 and 2026
  • Figure 48: Latin America Therapeutic Plasma Exchange Market Value Share Analysis by End-user, 2017 and 2026
  • Figure 49: Latin America Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 50: Latin America Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication
  • Figure 51: Latin America Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user
  • Figure 52: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 53: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-Region
  • Figure 54: Middle East & Africa Therapeutic Plasma Exchange Market Value Share Analysis by Disease Indication, 2017 and 2026
  • Figure 55: Middle East & Africa Therapeutic Plasma Exchange Market Value Share Analysis by End-user, 2017 and 2026
  • Figure 56: Middle East & Africa Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-Region, 2017 and 2026
  • Figure 57: Middle East & Africa Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication
  • Figure 58: Middle East & Africa Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user
目次

Title:
Therapeutic Plasma Exchange Market (Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders; End use - Hospitals, Specialty Clinics, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Global Therapeutic Plasma Exchange Market: Scope and Methodology

This report analyzes the current and future prospects of the global therapeutic plasma exchange market. The report comprises a comprehensive executive summary, including a market snapshot that provides overall information of various segments. The report is a combination of primary and secondary research. Primary research formed the bulk of the research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2016 to 2026, considering the macro and micro environmental factors. Growth rates for each segment within the global therapeutic plasma exchange market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the overview section. The report also provides insights into the key trends of the therapeutic plasma exchange market such as rise in prevalence of autoimmune diseases, cost advantage over IVIG treatment, and improvement in health care infrastructure in emerging economies. Key market indicators influencing the global therapeutic plasma exchange market, including cost constraints and regulatory landscape, have been taken into consideration. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global therapeutic plasma exchange market.

Market revenue in terms of US$ Mn for the period between 2016 and 2026 along with the compound annual growth rate (CAGR %) from 2018 to 2026 are provided for all the segments, considering 2017 as the base year. The year-on-year growth of the global therapeutic plasma exchange market for each segment is also provided. Additionally, market-related factors such as favorable reimbursement scenario, expanding applications in chronic diseases, side effects associated with plasmapheresis and historical year-on-year growth have been taken into consideration while estimating the market size.

Global Therapeutic Plasma Exchange Market: Segmentation

Based on disease indication, the global therapeutic plasma exchange market has been segmented into neurological disorders, renal disorders, hematology disorders, metabolic disorders, and others. The neurological disorders segment has been classified into chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, multiple sclerosis, neuromyelitis optica, and Guillain-Barre syndrome. The renal disorders segment has been categorized into post-renal transplant rejection, anti-glomerular basement membrane (anti-GMB) disease, and Wegener's granulomatosis. The hematology disorders segment has been divided into thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, cryoglobulinemia, multiple myeloma, metabolic disorders, familial hypercholesterolaemia (homozygous), and fulminant Wilson disease. In terms of end-user, the market has been classified into hospitals, specialty clinics, and ambulatory surgical centers. The hospitals segment is expected to dominate the market during the forecast period.

In terms of region, the global therapeutic plasma exchange market has been segment into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been divided into major countries/sub-regions in each of the regions. These include the U.S., Canada, the U.K., Germany, Russia, France, Italy, Spain, China, Australia, Japan, India, Brazil, GCC Countries, South Africa, and Mexico.

Global Therapeutic Plasma Exchange Market: Competitive Landscape

The report also profiles major players in the global therapeutic plasma exchange market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Asahi Kasei Corporation, Baxter International, Inc., Terumo Corporation, B. Braun Melsungen AG, Fresenius Kabi AG, Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation, Hemacare Corporation, and Medica S.p.A.

The global therapeutic plasma exchange market has been segmented as follows:

Global Therapeutic Plasma Exchange Market, by Disease Indication

  • Neurological Disorders
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Myasthenia Gravis
    • Multiple Sclerosis
    • Neuromyelitis Optica
    • Guillain-Barre Syndrome
  • Renal Disorders
    • Post-renal Transplant Rejection
    • Anti-GBM (Glomerular Basement Membrane) Disease
    • Wegener's Granulomatosis
  • Hematology Disorders
    • Thrombotic Thrombocytopenic Purpura
    • Hemolytic Uremic Syndrome
    • Cryoglobulinemia
    • Multiple Myeloma
  • Metabolic Disorders
    • Familial Hypercholesterolaemia (homozygous)
    • Fulminant Wilson Disease
  • Others

Global Therapeutic Plasma Exchange Market, by End-user

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

Global Therapeutic Plasma Exchange Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Australia & New Zealand
    • Japan
    • China
    • India
    • Rest of Asia pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

Table of Contents

Section 1: Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

Section 2: Assumptions and Research Methodology

  • 2.1. Assumptions
  • 2.2. Research Methodology

Section 3: Executive Summary

  • 3.1. Global Therapeutic Plasma Exchange Market Snapshot
  • 3.2. Market Share Analysis by Region, 2017

Section 4: Market Overview

  • 4.1. Therapeutic Plasma Exchange Market Taxonomy
  • 4.2. Global Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, 2016-2026
  • 4.3. Global Therapeutic Plasma Exchange Market: Market Outlook
  • 4.4. Key Industry Events

Section 5: Market Dynamics

  • 5.1. Drivers and Restraints Snapshot Analysis
  • 5.2. Drivers
  • 5.3. Restraints
    • 5.3.3. Lack of skilled professional
  • 5.4. Opportunities
  • 5.5. Key Trends
  • 5.6. Pipeline Analysis
  • 5.7. Clinical Efficacy of Therapeutic Plasma Exchange in Major Indications
  • 5.8. Global Therapeutic Plasma Exchange (TPE) Market Reimbursement Scenario
  • 5.9. Global Prevalence Rate of Major Diseases
  • 6.0. Healthcare Overview

Section 6: Global Therapeutic Plasma Exchange Market: Number of TPE Procedures, by Country/Sub-region

Section 7: Global Therapeutic Plasma Exchange Market Analysis, by Disease Indication

  • 7.1. Introduction
  • 7.2. Global Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication
  • 7.3. Global Therapeutic Plasma Exchange Market Forecast, by Disease Indication
    • 7.3.1. Neurological Disorders
      • 7.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
      • 7.3.1.2. Myasthenia Gravis
      • 7.3.1.3. Multiple Sclerosis
      • 7.3.1.4. Neuromyelitis Optica
      • 7.3.1.5. Guillain-Barre Syndrome
    • 7.3.2. Renal Disorders
      • 7.3.2.1. Post-renal Transplant Rejection
      • 7.3.2.2. Anti-GBM (Glomerular Basement Membrane) Disease
      • 7.3.2.3. Wegener's Granulomatosis
    • 7.3.3. Hematology Disorders
      • 7.3.3.1. Thrombotic Thrombocytopenic Purpura
      • 7.3.3.2. Hemolytic Uremic Syndrome
      • 7.3.3.3. Cryoglobulinemia
      • 7.3.3.4. Multiple Myeloma
    • 7.3.4. Metabolic Disorders
      • 7.3.4.1. Familial Hypercholesterolaemia (homozygous)
      • 7.3.4.2. Fulminant Wilson Disease
    • 7.3.5. Others
  • 7.4. Market Attractiveness Analysis, by Disease Indication

Section 8: Global Therapeutic Plasma Exchange Market Analysis, by End-user

  • 8.1. Introduction
  • 8.2. Global Therapeutic Plasma Exchange Market Value Share Analysis, by End-user
  • 8.3. Global Therapeutic Plasma Exchange Market Forecast, by End-user
    • 8.3.1. Hospitals
    • 8.3.2. Specialty Clinics
    • 8.3.3. Ambulatory Surgical Centers
  • 8.4. Market Attractiveness Analysis, by End-user

Section 9: Global Therapeutic Plasma Exchange Market Analysis, by Region

  • 9.1. Global Therapeutic Plasma Exchange Market Value Share Analysis, by Region
  • 9.2. Global Therapeutic Plasma Exchange Market Forecast, by Region
  • 9.3. Market Attractiveness Analysis, by Region

Section 10: North America Therapeutic Plasma Exchange Market Analysis

  • 10.1. Market Overview
  • 10.2. Market Analysis, by Disease Indication
    • 10.2.1. Market Value Share Analysis, by Disease Indication
    • 10.2.2. Market Size (US$ Mn) Forecast, by Disease Indication
      • 10.2.2.1. Neurological Disorders
        • 10.2.2.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
        • 10.2.2.1.2. Myasthenia Gravis
        • 10.2.2.1.3. Multiple Sclerosis
        • 10.2.2.1.4. Neuromyelitis Optica
        • 10.2.2.1.5. Guillain-Barre Syndrome
      • 10.2.2.2. Renal Disorders
        • 10.2.2.2.1. Post-renal Transplant Rejection
        • 10.2.2.2.2. Anti-GBM (Glomerular Basement Membrane) Disease
        • 10.2.2.2.3. Wegener's Granulomatosis
      • 10.2.2.3. Hematology Disorders
        • 10.2.2.3.1. Thrombotic Thrombocytopenic Purpura
        • 10.2.2.3.2. Hemolytic Uremic Syndrome
        • 10.2.2.3.3. Cryoglobulinemia
        • 10.2.2.3.4. Multiple Myeloma
      • 10.2.2.4. Metabolic Disorders
        • 10.2.2.4.1. Familial Hypercholesterolaemia (homozygous)
        • 10.2.2.4.2. Fulminant Wilson disease
      • 10.2.2.5. Others
  • 10.3. Market Analysis, by End-user
    • 10.3.1. Market Value Share Analysis, by End-user
    • 10.3.2. Market Size (US$ Mn) Forecast, by End-user
      • 10.3.2.1. Hospitals
      • 10.3.2.2. Specialty Clinics
      • 10.3.2.3. Ambulatory Surgical Centers
  • 10.4. Market Analysis, by Country
    • 10.4.1. Market Value Share Analysis, by Country
    • 10.4.2. Market Size (US$ Mn) Forecast, by Country, 2018-2026
      • 10.4.2.1. U.S.
      • 10.4.2.2. Canada
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Country
    • 10.5.2. By Disease Indication
    • 10.5.3. By End-user

Section 11: Europe Therapeutic Plasma Exchange Market Analysis

  • 11.1. Market Overview
  • 11.2. Market Analysis, by Disease Indication
    • 11.2.1. Market Value Share Analysis, by Disease Indication
    • 11.2.2. Market Size (US$ Mn) Forecast, by Disease Indication
      • 11.2.2.1. Neurological Disorders
        • 11.2.2.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
        • 11.2.2.1.2. Myasthenia Gravis
        • 11.2.2.1.3. Multiple Sclerosis
        • 11.2.2.1.4. Neuromyelitis Optica
        • 11.2.2.1.5. Guillain-Barre Syndrome
      • 11.2.2.2. Renal Disorders
        • 11.2.2.2.1. Post-renal Transplant Rejection
        • 11.2.2.2.2. Anti-GBM (Glomerular Basement Membrane) Disease
        • 11.2.2.2.3. Wegener's Granulomatosis
      • 11.2.2.3. Hematology Disorders
        • 11.2.2.3.1. Thrombotic Thrombocytopenic Purpura
        • 11.2.2.3.2. Hemolytic Uremic Syndrome
        • 11.2.2.3.3. Cryoglobulinemia
        • 11.2.2.3.4. Multiple Myeloma
      • 11.2.2.4. Metabolic Disorders
        • 11.2.2.4.1. Familial Hypercholesterolaemia (homozygous)
        • 11.2.2.4.2. Fulminant Wilson Disease
      • 11.2.2.5. Others
  • 11.3. Market Analysis, by End-user
    • 11.3.1. Market Value Share Analysis, by End-user
    • 11.3.2. Market Size (US$ Mn) Forecast, by End-user
      • 11.3.2.1. Hospitals
      • 11.3.2.2. Specialty Clinics
      • 11.3.2.3. Ambulatory Surgical Centers
  • 11.4. Market Analysis, by Country/Sub-region
    • 11.4.1. Market Value Share Analysis, by Country/Sub-region
    • 11.4.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2026
      • 11.4.2.1. Germany
      • 11.4.2.2. U.K.
      • 11.4.2.3. France
      • 11.4.2.4. Spain
      • 11.4.2.5. Italy
      • 11.4.2.6. Russia
      • 11.4.2.7. Rest of Europe
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Country/Sub-region
    • 11.5.2. By Disease Indication
    • 11.5.3. By End-user

Section 12: Asia Pacific Therapeutic Plasma Exchange Market Analysis

  • 12.1. Market Overview
  • 12.2. Market Analysis, by Disease Indication
    • 12.2.1. Market Value Share Analysis, by Disease Indication
    • 12.2.2. Market Size (US$ Mn) Forecast, by Disease Indication
      • 12.2.2.1. Neurological Disorders
        • 12.2.2.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
        • 12.2.2.1.2. Myasthenia Gravis
        • 12.2.2.1.3. Multiple Sclerosis
        • 12.2.2.1.4. Neuromyelitis Optica
        • 12.2.2.1.5. Guillain-Barre Syndrome
      • 12.2.2.2. Renal Disorders
        • 12.2.2.2.1. Post-renal Transplant Rejection
        • 12.2.2.2.2. Anti-GBM (Glomerular Basement Membrane) Disease
        • 12.2.2.2.3. Wegener's Granulomatosis
      • 12.2.2.3. Hematology Disorders
        • 12.2.2.3.1. Thrombotic Thrombocytopenic Purpura
        • 12.2.2.3.2. Hemolytic Uremic Syndrome
        • 12.2.2.3.3. Cryoglobulinemia
        • 12.2.2.3.4. Multiple Myeloma
      • 12.2.2.4. Metabolic Disorders
        • 12.2.2.4.1. Familial Hypercholesterolaemia (homozygous)
        • 12.2.2.4.2. Fulminant Wilson Disease
      • 12.2.2.5. Others
  • 12.3. Market Analysis, by End-user
    • 12.3.1. Market Value Share Analysis, by End-user
    • 12.3.2. Market Size (US$ Mn) Forecast, by End-user
      • 12.3.2.1. Hospitals
      • 12.3.2.2. Specialty Clinics
      • 12.3.2.3. Ambulatory Surgical Centers
  • 12.4. Market Analysis, by Country/Sub-region
    • 12.4.1. Market Value Share Analysis, by Country/Sub-region
    • 12.4.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2026
      • 12.4.2.1. China
      • 12.4.2.2. Japan
      • 12.4.2.3. India
      • 12.4.2.4. Australia & New Zealand
      • 12.4.2.5. Rest of Asia Pacific
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Country/Sub-region
    • 12.5.2. By Disease Indication
    • 12.5.3. By End-user

Section 13: Latin America Therapeutic Plasma Exchange Market Analysis

  • 13.1. Market Overview
  • 13.2. Market Analysis, by Disease Indication
    • 13.2.1. Market Value Share Analysis, by Disease Indication
    • 13.2.2. Market Size (US$ Mn) Forecast, by Disease Indication
      • 13.2.2.1. Neurological Disorders
        • 13.2.2.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
        • 13.2.2.1.2. Myasthenia Gravis
        • 13.2.2.1.3. Multiple Sclerosis
        • 13.2.2.1.4. Neuromyelitis Optica
        • 13.2.2.1.5. Guillain-Barre Syndrome
      • 13.2.2.2. Renal Disorders
        • 13.2.2.2.1. Post-renal Transplant Rejection
        • 13.2.2.2.2. Anti-GBM (Glomerular Basement Membrane) Disease
        • 13.2.2.2.3. Wegener's Granulomatosis
      • 13.2.2.3. Hematology Disorders
        • 13.2.2.3.1. Thrombotic Thrombocytopenic Purpura
        • 13.2.2.3.2. Hemolytic Uremic Syndrome
        • 13.2.2.3.3. Cryoglobulinemia
        • 13.2.2.3.4. Multiple Myeloma
      • 13.2.2.4. Metabolic Disorders
        • 13.2.2.4.1. Familial Hypercholesterolaemia (homozygous)
        • 13.2.2.4.2. Fulminant Wilson Disease
      • 13.2.2.5. Others
  • 13.3. Market Analysis, by End-user
    • 13.3.1. Market Value Share Analysis, by End-user
    • 13.3.2. Market Size (US$ Mn) Forecast, by End-user
      • 13.3.2.1. Hospitals
      • 13.3.2.2. Specialty Clinics
      • 13.3.2.3. Ambulatory Surgical Centers
  • 13.4. Market Analysis, by Country/Sub-region
    • 13.4.1. Market Value Share Analysis, by Country/Sub-region
    • 13.4.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2026
      • 13.4.2.1. Brazil
      • 13.4.2.2. Mexico
      • 13.4.2.3. Rest of Latin America
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Country/Sub-region
    • 13.5.2. By Disease Indication
    • 13.5.3. By End-user

Section 14: Middle East & Africa Therapeutic Plasma Exchange Market Analysis

  • 14.1. Market Overview
  • 14.2. Market Analysis, by Disease Indication
    • 14.2.1. Market Value Share Analysis, by Disease Indication
    • 14.2.2. Market Size (US$ Mn) Forecast, by Disease Indication
      • 14.2.2.1. Neurological Disorders
        • 14.2.2.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
        • 14.2.2.1.2. Myasthenia Gravis
        • 14.2.2.1.3. Multiple Sclerosis
        • 14.2.2.1.4. Neuromyelitis Optica
        • 14.2.2.1.5. Guillain-Barre Syndrome
      • 14.2.2.2. Renal Disorders
        • 14.2.2.2.1. Post-renal Transplant Rejection
        • 14.2.2.2.2. Anti-GBM (Glomerular Basement Membrane) Disease
        • 14.2.2.2.3. Wegener's Granulomatosis
      • 14.2.2.3. Hematology Disorders
        • 14.2.2.3.1. Thrombotic Thrombocytopenic Purpura
        • 14.2.2.3.2. Hemolytic Uremic Syndrome
        • 14.2.2.3.3. Cryoglobulinemia
        • 14.2.2.3.4. Multiple Myeloma
      • 14.2.2.4. Metabolic Disorders
        • 14.2.2.4.1. Familial Hypercholesterolaemia (homozygous)
        • 14.2.2.4.2. Fulminant Wilson Disease
      • 14.2.2.5. Others
  • 14.3. Market Analysis, by End-user
    • 14.3.1. Market Value Share Analysis, by End-user
    • 14.3.2. Market Size (US$ Mn) Forecast, by End-user
      • 14.3.2.1. Hospitals
      • 14.3.2.2. Specialty Clinics
      • 14.3.2.3. Ambulatory Surgical Centers
  • 14.4. Market Analysis, by Country/Sub-region
    • 14.4.1. Market Value Share Analysis, by Country/Sub-region
    • 14.4.2. Market Size (US$ Mn) Forecast, by Country, 2018-2026
      • 14.4.2.1. GCC Countries
      • 14.4.2.2. South Africa
      • 14.4.2.3. Israel
      • 14.4.2.4. Rest of MEA
  • 14.5. Market Attractiveness Analysis
    • 14.5.1. By Country/Sub-region
    • 14.5.2. By Disease Indication
    • 14.5.3. By End-user

Section 15: Company Profiles

  • 15.1. Competition Matrix
  • 15.3. Company Profiles
    • 15.2.1. Asahi Kasei Corporation
      • 15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.1.2. Financial Overview
      • 15.2.1.3. Product Portfolio
      • 15.2.1.4. SWOT Analysis
      • 15.2.1.5. Strategic Overview
    • 15.2.2. Baxter International, Inc.
      • 15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.2.2. Financial Overview
      • 15.2.2.3. Product Portfolio
      • 15.2.2.4. SWOT Analysis
      • 15.2.2.5. Strategic Overview
    • 15.2.3. Terumo Corporation
      • 15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.3.2. Financial Overview
      • 15.2.3.3. Product Portfolio
      • 15.2.3.4. SWOT Analysis
      • 15.2.3.5. Strategic Overview
    • 15.2.4. B. Braun Melsungen AG
      • 15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.4.2. Financial Overview
      • 15.2.4.3. Product Portfolio
      • 15.2.4.4. SWOT Analysis
      • 15.2.4.5. Strategic Overview
    • 15.2.5. Fresenius Kabi AG
      • 15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.5.2. Financial Overview
      • 15.2.5.3. Product Portfolio
      • 15.2.5.4. SWOT Analysis
      • 15.2.5.5. Strategic Overview
    • 15.2.6. Kawasumi Laboratories, Inc.
      • 15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.6.2. Financial Overview
      • 15.2.6.3. Product Portfolio
      • 15.2.6.4. SWOT Analysis
      • 15.2.6.5. Strategic Overview
    • 15.2.7. Haemonetics Corporation
      • 15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.7.2. Financial Overview
      • 15.2.7.3. Product Portfolio
      • 15.2.7.4. SWOT Analysis
      • 15.2.7.5. Strategic Overview
    • 15.2.8. Cerus Corporation
      • 15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.8.2. Financial Overview
      • 15.2.8.3. Product Portfolio
      • 15.2.8.4. SWOT Analysis
      • 15.2.8.5. Strategic Overview
    • 15.2.9. Hemacare Corporation
      • 15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.9.2. Financial Overview
      • 15.2.9.3. Product Portfolio
      • 15.2.9.4. SWOT Analysis
      • 15.2.9.5. Strategic Overview
    • 15.2.10. Medica S.p.A.
      • 15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.10.2. Financial Overview
      • 15.2.10.3. Product Portfolio
      • 15.2.10.4. SWOT Analysis
      • 15.2.10.5. Strategic Overview
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.